Altimmune nears a key MASH trial readout, with strong market potential and new liver and alcohol studies supporting growth.

Viking Therapeutics faces tough obesity drug rivals, with VK2735 showing promise but an uncertain edge. Find out why VKTX ...

GAITHERSBURG, Md., May 19, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and ...

GAITHERSBURG, Md., May 06, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2025 ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Altimmune (ALT – Research Report) and Alpha Tau Medical Ltd (DRTS – Research R ...

Other groups working on universal flu vaccines include GSK/CureVac, Sanofi, Pfizer, Novavax, FluGen, Vivaldi Biosciences, CodaGenix, BiondVax Pharma, ConserV Bioscience/Imutex, Altimmune ...

Symvivo also has an oral candidate in a phase 1 study which started last November. Altimmune meanwhile is taking a different tack with its single-dose intranasal candidate AdCOVID, which had been ...

Find the latest Altimmune, Inc. (ALT) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.

The Obesity Drugs Market is experiencing unprecedented growth, driven by increasing global obesity rates, sedentary ...

Visit a quote page and your recently viewed tickers will be displayed here.